Research programme: antibody-drug conjugates - Sorrento Therapeutics

Drug Profile

Research programme: antibody-drug conjugates - Sorrento Therapeutics

Alternative Names: AfDCs - Sorrento Therapeutics; Antibody-formulated drug conjugates - Sorrento Therapeutics; STI-0602; ZV05 ADCs - Sorrento Therapeutics

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Sorrento Therapeutics
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Proto oncogene protein c met modulators; Vascular endothelial growth factor receptor-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 25 Nov 2016 Concortis Biotherapeutics announces intention to submit IND by June 2017 (Concortis Biotherapeutics pipeline, November 2016)
  • 14 Apr 2016 Preclinical trials in Non-small cell lung cancer in USA (Parenteral)
  • 08 Dec 2014 Preclinical trials in Breast cancer in USA (Parenteral) prior to December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top